Articles by Tyler Menichiello

  1. FDA Releases Draft Guidance To Accelerate Biosimilar Development 10/31/2025

    New FDA draft guidance aims to reduce the timeline and cost of developing biosimilars.

  2. Supporting The Next Generation Of ADCs 10/30/2025

    Experts discuss innovation in antibody-drug conjugate (ADC) technology and how these impact CMC strategy. This summary captures key takeaways from the Bioprocess Online Live event "Evolving CMC Strategies To Enable Next-Gen ADCs."

  3. AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing 10/10/2025

    At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.

  4. On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration 9/29/2025

    AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.

  5. On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing 9/26/2025

    Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.

  6. On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D. 9/25/2025

    DeciBio partner Carl Schoellhammer, Ph.D., speaks on the record with Bioprocess Online's chief editor Tyler Menichiello at the 2025 BioProcess International conference in Boston.

  7. Single-Use Standardization Starts At Home 8/28/2025

    During a Bioprocess Online Live event, “Single-Use Harmonization Needs A Tune Up," panelists discuss a way forward for the industry to unlock the true flexibility and promise of single-use technology.

  8. Unlocking The Pharmacological Potential Of Antibodies 8/20/2025

    Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.

  9. How Lumen Is Putting The "Farm" In Biopharma 7/31/2025

    Lumen Bioscience's SVP of production and development, Craig Behnke, Ph.D., explains how the company is cutting costs and rethinking upstream manufacturing with its algae-based production platform.

  10. The Safety Potential Of Conditionally Active Biologics 7/28/2025

    Conditionally active biologics (CABs) are an emerging class of therapies that can reduce off-target toxicity in the clinic, and they were a topic of conversation at the 2025 BIO International Convention.